Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy

No Thumbnail Available
File version
Author(s)
Thompson, Andrew M
O'Connor, Patrick D
Marshall, Andrew J
Francisco, Amanda F
Kelly, John M
Riley, Jennifer
Read, Kevin D
Perez, Catherine J
Cornwall, Scott
Thompson, RC Andrew
Keenan, Martine
White, Karen L
Charman, Susan A
Zulfiqar, Bilal
Sykes, Melissa L
Avery, Vicky M
Chatelain, Eric
Denny, William A
Primary Supervisor
Other Supervisors
Editor(s)
Date
2020
Size
File type(s)
Location
License
Abstract

Phenotypic screening of a 900 compound library of antitubercular nitroimidazole derivatives related to pretomanid against the protozoan parasite Trypanosoma cruzi (the causative agent for Chagas disease) identified several structurally diverse hits with an unknown mode of action. Following initial profiling, a first proof-of-concept in vivo study was undertaken, in which once daily oral dosing of a 7-substituted 2-nitroimidazooxazine analogue suppressed blood parasitemia to low or undetectable levels, although sterile cure was not achieved. Limited hit expansion studies alongside counter-screening of new compounds targeted at visceral leishmaniasis laid the foundation for a more in-depth assessment of the best leads, focusing on both drug-like attributes (solubility, metabolic stability and safety) and maximal killing of the parasite in a shorter timeframe. Comparative appraisal of one preferred lead (58) in a chronic infection mouse model, monitored by highly sensitive bioluminescence imaging, provided the first definitive evidence of (partial) curative efficacy with this promising nitroimidazooxazine class.

Journal Title

Eur J Med Chem

Conference Title
Book Title
Edition
Volume

207

Issue
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject

Medicinal and biomolecular chemistry

Organic chemistry

Pharmacology and pharmaceutical sciences

Bioluminescence imaging

Chagas disease

In vivo efficacy

Library screening

Pharmacokinetics

Persistent link to this record
Citation

Thompson, AM; O'Connor, PD; Marshall, AJ; Francisco, AF; Kelly, JM; Riley, J; Read, KD; Perez, CJ; Cornwall, S; Thompson, RCA; Keenan, M; White, KL; Charman, SA; Zulfiqar, B; Sykes, ML; Avery, VM; Chatelain, E; Denny, WA, Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy., Eur J Med Chem, 2020, 207

Collections